Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS.
Ivo Carre, PhD
Advertisement
Ivo Carre, PhD, is a senior business analyst at Lifescience Dynamics.
Articles by Ivo Carre, PhD
New data in high-risk MDS, emerging menin inhibitors in AML, and evolving care needs in rare bleeding disorders set the stage for major ASH 2025 discussions.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
2
Top 5 Most-Read Vaccine Content in 2025
3
Real-World Data Highlight Favorable Responses to Liso-Cel for R/R CLL
4
Baricitinib Shows Real-World Effectiveness in Severe Alopecia Areata Hair Loss
5
